课题基金 / 基金详情

Correcting monogenic skin diseases in situ: Assessing the potential of topically applicable gene therapy.

Correcting monogenic skin diseases in situ: Assessing the potential of topically applicable gene therapy.
原位纠正单基因皮肤病：评估局部适用基因疗法的潜力。
批准号：
400904
负责人：
Hedtrich Sarah
金额：
$34.44万
依托单位：
University of British Columbia
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2019
资助国家：
加拿大
项目状态：
已结题
起止时间：
2019-03-01 至 2022-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=400904&lang=en
关键词：
3d Skin Disease Models Autosomal Recessive Congenital Ichthyosis Crispr-Cas9 Gene Editing Monogenic Skin Disease Nanocarriers For Topical Drug Delivery Novel Treatment Options For Orphan Disease Topical Delivery Of Biomacromolecules

项目摘要

项目成果

Hedtrich Sarah的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Monogenic skin diseases such as autosomal recessive congenital ichthyosis (ARCI) are caused by mutations in a single gene. If these mutations could be corrected, the disease should be mitigated. Indeed, for recessively inherited conditions such as ARCI, c
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting TSLP - Novel anti-inflammatory compounds for the treatment and prevention of atopic diseases
  • 批准号：
    419584
  • 项目类别：
    Operating Grants
  • 资助金额：
    $58.52万
  • 财政年份：
    2020
  • 负责人：
    Hedtrich Sarah
  • 依托单位：
    University of British Columbia
海外基金